Table 2.

Cryoablation combined with immune checkpoint inhibitors.

NCT ID	Title	Type of immune therapy combined with cryoablation	Phase
NCT02833233	A study of pre-operative treatment with cryoablation and immune therapy in early stage breast cancer	Ipilimumab and nivolumab	Not applicable
NCT03546686	Peri-operative ipilimumab + nivolumab and cryoablation vs. standard care in women with triple-negative breast cancer	Ipilimumab and nivolumab	Phase II
NCT02489357	Pembrolizumab and cryosurgery in treating patients with newly diagnosed, oligo-metastatic prostate cancer	Pembrolizumab	Not applicable
NCT02626130	Pilot study of presurgical tremelimumab with or without cryoablation in patients with metastatic renal cell carcinoma	Tremelimumab	Phase I
NCT03189186	Phase-I Trial of pembrolizumab and percutaneous cryoablation combination followed by nephron-sparing surgery or cytoreductive nephrectomy in locally advanced and metastatic renal cell carcinomas	Pembrolizumab	Phase I
NCT02821754	A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (hcc) or biliary tract carcinomas (btc)	Tremelimumab and durvalumab	Phase II
NCT03457948	Pembrolizumab and liver-directed therapy in treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive liver metastases	Pembrolizumab	Phase II